Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics

(Ingelheim, Germany, Oxford, UK, and Boston, USA, Feb 26, 2026) by Linda Ruckel and Dr Reinhard Malin.

• The preclinical, small molecule program offers a potential first-in-class, oral, precision immunometabolic approach to modulating disease-driving immune cells
• Deal includes upfront and milestone payments to Sitryx totaling over US $500 million, plus tiered royalties
• Exclusive license expands Boehringer’s preclinical immunology pipeline, aiming to improve patient outcomes

Sitryx receives both upfront and near-term payments and is eligible to receive potential development, regulatory, and commercialization milestone payments totaling more than $500 million, in addition to tiered royalties on future sales.